Literature DB >> 11522734

Intragastric volatile N-nitrosamines, nitrite, pH, and Helicobacter pylori during long-term treatment with omeprazole.

I T Vermeer1, L G Engels, D M Pachen, J W Dallinga, J C Kleinjans, J M van Maanen.   

Abstract

BACKGROUND & AIMS: This study evaluated the effect of long-term gastric acid suppressive therapy with omeprazole on intragastric levels of carcinogenic N-nitrosamines and related parameters.
METHODS: Forty-five patients on long-term omeprazole medication (mean, 35 months) and 13 healthy subjects without medication participated. Volatile N-nitrosamines were determined in gastric juice and urine. Intragastric pH, nitrite, nitrate, and H. pylori status were determined. DNA isolated from gastric biopsy specimens was analyzed for precarcinogenic alkyl-DNA adducts.
RESULTS: The intragastric pH in patients was significantly higher compared with controls (P = 0.0001). Gastric nitrite levels in patients were nonsignificantly higher. There was no difference in total levels of intragastric volatile N-nitrosamines between patients and controls, however, urinary N-nitrosodimethylamine excretion was higher in patients (P = 0.001). On omeprazole, Helicobacter pylori-positive vs. -negative patients had a nonsignificantly higher intragastric nitrite level and higher urinary N-nitrosodimethylamine excretion. No alkyl-DNA adducts could be detected in gastric epithelium.
CONCLUSIONS: Increased intragastric pH caused by long-term treatment with omeprazole does not result in increased intragastric levels of nitrite and volatile N-nitrosamines. The significantly higher urinary N-nitrosamine excretion implies the risk of increased endogenous formation of N-nitrosamines during long-term omeprazole treatment. This risk may be higher in H. pylori-positive patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522734     DOI: 10.1053/gast.2001.27098

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  Inflammatory bowel disease stimulates formation of carcinogenic N-nitroso compounds.

Authors:  T M C M de Kok; L G J B Engels; E J Moonen; J C S Kleinjans
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

2.  Larger amounts of nitrite and nitrate-reducing bacteria in megaesophagus of Chagas' disease than in controls.

Authors:  D Pajecki; B Zilberstein; I Cecconello; M A A Dos Santos; O K Yagi; J J Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2007-02       Impact factor: 3.452

3.  Which is the best choice for gastroesophageal disorders: Melatonin or proton pump inhibitors?

Authors:  Joanna Dulce Favacho de Oliveira Torres; Ricardo de Souza Pereira
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-10-06

4.  Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study.

Authors:  M C Bradley; L J Murray; M M Cantwell; C M Hughes
Journal:  Br J Cancer       Date:  2011-11-22       Impact factor: 7.640

Review 5.  Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients.

Authors:  Sabrina Cardile; Claudio Romano
Journal:  Adolesc Health Med Ther       Date:  2012-02-28

6.  Caenorhabditis elegans to Model the Capacity of Ascorbic Acid to Reduce Acute Nitrite Toxicity under Different Feed Conditions: Multivariate Analytics on Behavioral Imaging.

Authors:  Samuel Verdu; Alberto J Perez; Conrado Carrascosa; José M Barat; Pau Talens; Raúl Grau
Journal:  Int J Environ Res Public Health       Date:  2021-02-20       Impact factor: 3.390

Review 7.  One stomach, two subtypes of carcinoma-the differences between distal and proximal gastric cancer.

Authors:  Yuan Zhang; Peng-Shan Zhang; Ze-Yin Rong; Chen Huang
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-11-15

Review 8.  The stomach in health and disease.

Authors:  R H Hunt; M Camilleri; S E Crowe; E M El-Omar; J G Fox; E J Kuipers; P Malfertheiner; K E L McColl; D M Pritchard; M Rugge; A Sonnenberg; K Sugano; J Tack
Journal:  Gut       Date:  2015-09-04       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.